QIAGEN Website    Quick Order    Online Seminar    Contact    My Account
Home  >  Resources  >  Pathway References

Pathway References: Cancer Drug Targets

  1. Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):114-22.
  2. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008 Oct;7(10):3129-40.
  3. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35.
  4. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):54-72.
  5. Lavecchia A, Di Giovanni C, Novellino E. CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy. Curr Med Chem. 2009;16(15):1831-49.
  6. Dangle PP, Zaharieva B, Jia H, Pohar KS. Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer. Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):125-36.
  7. Zahorowska B, Crowe PJ, Yang JL. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol. 2009 Sep;135(9):1137-48. Epub 2009 Jun 17.
  8. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009 Jul;9(7):463-75. Epub 2009 Jun 18.
  9. Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L. Glutathione transferases as targets for cancer therapy. Anticancer Agents Med Chem. 2009 Sep;9(7):763-77. Epub 2009 Sep 1.
  10. Carpinelli P, Moll J. Is there a future for Aurora kinase inhibitors for anticancer therapy?. Curr Opin Drug Discov Devel. 2009 Jul;12(4):533-42.
  11. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
  12. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009 Aug 27;28(34):3009-21. Epub 2009 Jul 6.
  13. Prodromou C. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90. Curr Top Med Chem. 2009;9(15):1352-68.
  14. Dickens MP, Fitzgerald R, Fischer PM. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol. 2010 Feb;20(1):10-8. Epub 2009 Nov 6.
  15. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010 Jan;14(1):45-55.
  16. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs. 2010 Jan;19(1):27-43.
  17. Pentimalli F, Giordano A. Promises and drawbacks of targeting cell cycle kinases in cancer. Discov Med. 2009 Dec;8(43):177-80.
  18. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010 Mar 15;70(6):2146-57. Epub 2010 Feb 23.
  19. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 1;16(5):1384-90. Epub 2010 Feb 23.
  20. Gimenez Ortiz A, Montalar Salcedo J. Heat shock proteins as targets in oncology. Clin Transl Oncol. 2010 Mar;12(3):166-73.
  21. Goetsch L, Corvaia N. Insulin-like growth factor receptor type I as a target for cancer therapy. Immunotherapy. 2009 Mar;1(2):265-79.
  22. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010 Aug;9(8):643-60.
  23. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell. 2005 Jan;7(1):25-37.
  24. Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev. 2005 Feb;15(1):62-8.
  25. Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br J Cancer. 2006 Feb 13;94(3):341-5.
  26. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, Morelli MP, Cascone T, Tortora G. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol. 2006 Jun;17 Suppl 7:vii109-14.
  27. Zaffaroni N, Pennati M, Folini M. Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol Biol. 2007;361:239-63.
  28. Goossens L, Pommery N, Henichart JP. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy. Curr Top Med Chem. 2007;7(3):283-96.
  29. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97:247-74.
  30. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98.
  31. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007;39(7-8):1476-82. Epub 2007 Apr 8.
  32. Nakanishi T. Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics. 2007 May-Jun;4(3):241-54.
  33. Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007;67(14):2045-75.
  34. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2008 Jan;29(1):22-8. Epub 2007 Nov 26.
  35. Wee S, Lengauer C, Wiederschain D. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. Curr Opin Oncol. 2008 Jan;20(1):77-82.
  36. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, Gius D. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des. 2007;13(33):3368-77.
  37. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008 Jan;8(1):61-70.
  38. Caraglia M, Marra M, Meo G, Addeo SR, Tagliaferri P, Budillon A. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy. Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):209-22.
  39. Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):119-34.
  40. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15;14(6):1639-48.